CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript - Thomson StreetEvents

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript - Thomson StreetEvents
CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript
Published Jul 01, 2021
16 pages (9699 words) — Published Jul 01, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

  
Brief Excerpt:

...Thank you, Sarah. Ladies and gentlemen, a warm welcome to this conference call from us here at CureVac. Over the last -- past 6 months, we have been conducting a pivotal Phase IIb/III efficacy trial called HERALD study, our first-generation COVID-19 vaccine candidate, CVnCoV. Conducted in 10 countries and across 2 continents in Europe and Latin America, the HERALD study is so far unmatched by similar trials in terms of geographic diversity and even more important in terms of increasingly challenging variant rich environments the vaccine faced....

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
CureVac NV
Ticker
CVAC.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I have a few. First one is I'm trying to understand the delta variants specifically. The -- it's -- in your chart, you showed Delta variant is quite prevalent in the regions that you tested your Phase III. But in the actual cases, it's vary to only 1%. I guess can you provide any color, any hypothesis you may have regarding this disconnect? That's the first question. The second question is around you look -- I think you looked at Slide 11, you looked at efficacy on different variants. I guess have you looked at moderate to severe cases, the efficacy across the Board and also the hospitalization and death, 6 cases, what are the variance in these 6 cases? This is the second question. The third question, I want to also ask about the age stratification. When you submit the application to EMA do you specify that you're looking for 18 to 60? Or you are going after the overall population?

Table Of Contents

CureVac NV Q4 2021 Earnings Call Summary – 2022-04-28 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Transcript – 2021-11-19 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary – 2021-10-12 – US$ 54.00 – Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript – 2021-10-12 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Updates On Clinical Trial - Corporate Call Transcript – 2021-06-17 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 17-Jun-21 12:00pm GMT

CureVac NV Q4 2020 Earnings Call Transcript – 2021-04-15 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 15-Apr-21 2:00pm GMT

CureVac N.V. - Special Call Transcript – 2021-02-05 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 5-Feb-21 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript" Jul 01, 2021. Alacra Store. May 01, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-Final-Analysis-of-Phase-2b-3-Clinical-Trial-Of-CVnCoV-Investor-Call-T14914802>
  
APA:
Thomson StreetEvents. (2021). CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript Jul 01, 2021. New York, NY: Alacra Store. Retrieved May 01, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-Final-Analysis-of-Phase-2b-3-Clinical-Trial-Of-CVnCoV-Investor-Call-T14914802>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.